Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Bone Marrow Transplant • Lymphoma • NCI-CCC Tumor Board Question • Internal Medicine • Hematology • Cleveland Clinic • NCI-CCC Lymphoma Tumor Board Question
What is your approach to curative-intent therapy for a young, fit patient with newly-diagnosed monomorphic epitheliotropic intestinal T cell lymphoma (MEITL)?
Do you incorporate PEG-asparaginase or brentuximab vedotin (for CD30-expressing malignant cells) into anthracycline-based induction regimens? Do you consolidate first remission with autologous or allogeneic hematopoietic cell transplant?
Answer from: Medical Oncologist at Academic Institution
If >= 10% of the cells express CD30 by IHC, I would treat with BV+CHP x 6 cycles rather than CHOP according to the ECHELON-2 trial (although this trial included only 3 patients with EATL). Historically, the 5-year OS rate with anthracycline-based chemotherapy alone is approximately 10 to 20%, so ...
Sign in or Register to read more